Kyverna Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	436	-	-	-
Enterprise Value	72	-49	-41	-71
PB Ratio	1.20	-	-	-
EV/Sales Ratio	-	-	-5.88	-12.56
EV/EBITDA Ratio	-	0.86	1.57	2.85
EV/EBIT Ratio	-	0.81	1.43	2.70
EV/FCF Ratio	-	0.92	1.12	3.03
Debt / Equity Ratio	0.03	-0.07	-0.14	-0.12
Debt / EBITDA Ratio	-	-0.16	-0.40	-0.22
Debt / FCF Ratio	-	-0.17	-0.29	-0.24
Quick Ratio	16.94	2.93	4.34	4.81
Current Ratio	17.17	3.06	4.46	4.84
Asset Turnover	-	0	0.09	-
Interest Coverage	-	-321.81	-443.51	-8782.33
Return on Equity (ROE)	-	58.80%	48.10%	-
Return on Assets (ROA)	-	-85.00%	-37.90%	-
Return on Capital (ROIC)	-	51.02%	46.32%	64.73%
Earnings Yield	-17.59%	-	-	-
Buyback Yield / Dilution	-5115.19%	-47.89%	-71.31%	-
Total Shareholder Return	-5115.19%	-47.89%	-71.31%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).